Doravirine Explained

Doravirine, sold under the brand name Pifeltro, is a non-nucleoside reverse transcriptase inhibitor medication developed by Merck & Co. for use in the treatment of HIV/AIDS.

Doravirine was approved for medical use in the United States in August 2018.^[1]

Doravirine is available in fixed-dose combinations with other HIV drugs such as doravirine/lamivudine/tenofovir (sold under the brand name Delstrigo).^[2]

Notes and References

1. Web site: Drug Approval Package: Pifeltro (doravirine) . U.S. Food and Drug Administration (FDA) . 9 October 2018 . 22 September 2020.
2. Web site: Delstrigo EPAR . European Medicines Agency (EMA). 4 August 2023 .